Promising data for dolutegravir and HIV combination therapy GS-9620 and PGT121: industry news round-up

This week sees the announcement of many clinical trial results at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI; 4–7 March) in Boston (MA, USA), with heavy focuses on HIV and tuberculosis. In addition, there are launches and new funding in the field of antibiotic development.
Our highlights from the latest industry headlines:
  • Sanofi and Evotec to collaborate on infectious disease portfolio
  • Preclinical data from Gilead supports continued investigation of GS-9620 and PGT121 as part of an HIV elimination strategy
  • Phase III data shows dolutegravir to be safe and well-tolerated in HIV–TB co-infected adults
  • Basilea launches Zevtera® (ceftobiprole) in Argentina
  • CARB-X commits funding to MicuRx Pharmaceuticals for Phase I study of novel polymixin antibiotic, MRX-8
  • Novel vaccine development platform, HydroVax™, to be driven forward by new partnership
    Restricted Content / Members Only

    You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment